The Radiation Therapy Oncology Group (RTOG) is the leading multicenter and multidisciplinary research organization systematically testing novel radiotherapy (RT) approaches against cancer and pursuing fully integrated translational research to enhance this effort. The group will build on its outstanding scientific accomplishments in the current funding period to conduct research based on three fundamental initiatives: 1. Physical Targeting: RTOG will implement and test advances in imaging and high-precision RT planning and delivery technologies in clinical trials. 2. Molecular Targeting: Combined with RT: RTOG will design and conduct hypothesis-driven trials testing the integration of novel molecular targeted anti-cancer agents with optimized RT or chemo-RT. 3. Translational Research: RTOG will implement powerful biostatistical and medical informatics approaches to its unique and inter-linked clinical, biophysical, biologic, and outcomes databases that will faciliate hypothesis-driven analyses of these resources. The RTOG's research is primarily directed toward patients with brain tumors, head and neck cancer, lung cancer, gastrointestinal cancer, and genitourinal cancer. More limited research strategies have been developed for patients with gynecologic and breast cancer and sarcoma. RTOG research is supported by outstanding contributions from the Advanced Technology Integration, the Translational Research Program, and the Health Services Research and Outcomes Committees as well as the newly relocated Biospecimen Resource and from the four core committees of Medical Oncology, Medical Physics, Pathology, and Surgical Oncology. These contributions are well coordinated by a strong administrative and scientific infrastructure and have resulted in increased productivity in the current as compared with the prior funding cycle in terms of: 1. publication record;2. clinical trials activated and completed;3. overall patient accrual;4. public and private funding of group research;5. collaboration with other cooperative groups and other NIH-funded organizations;and 6. increased participation and leadership of Canadian investigators, with 8 of 37 full member institutions being Canadian. Close to two-thirds of all cancer patients receive radiation therapy for cure or for symptom relief. Novel technology, molecular targeted drugs and advances in radiation and cancer biology will improve the success rate of radiation therapy through clinical research over the next six years.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
3U10CA021661-35S1
Application #
8322927
Study Section
Subcommittee G - Education (NCI)
Program Officer
Mooney, Margaret M
Project Start
1979-02-20
Project End
2014-12-31
Budget Start
2011-03-22
Budget End
2011-12-31
Support Year
35
Fiscal Year
2011
Total Cost
$2,923,989
Indirect Cost
Name
American College of Radiology
Department
Type
DUNS #
062485800
City
Reston
State
VA
Country
United States
Zip Code
20191
Ulrich, Connie M; Deshmukh, Snehal; Pugh, Stephanie L et al. (2018) Attrition in NRG Oncology's Radiation-Based Clinical Trials. Int J Radiat Oncol Biol Phys 102:26-33
Ali, Arif N; Zhang, Peixin; Yung, W K Alfred et al. (2018) NRG oncology RTOG 9006: a phase III randomized trial of hyperfractionated radiotherapy (RT) and BCNU versus standard RT and BCNU for malignant glioma patients. J Neurooncol 137:39-47
Lawrence, Yaacov R; Moughan, Jennifer; Magliocco, Anthony M et al. (2018) Expression of the DNA repair gene MLH1 correlates with survival in patients who have resected pancreatic cancer and have received adjuvant chemoradiation: NRG Oncology RTOG Study 9704. Cancer 124:491-498
Rogers, Leland; Zhang, Peixin; Vogelbaum, Michael A et al. (2018) Intermediate-risk meningioma: initial outcomes from NRG Oncology RTOG 0539. J Neurosurg 129:35-47
Raman, Srinivas; Ding, Keyue; Chow, Edward et al. (2018) Minimal clinically important differences in the EORTC QLQ-C30 and brief pain inventory in patients undergoing re-irradiation for painful bone metastases. Qual Life Res 27:1089-1098
Lieberman, Frank S; Wang, Meihua; Robins, H Ian et al. (2018) Phase 2 Study of Radiation Therapy Plus Low Dose Temozolomide Followed by Temozolomide and Irinotecan for Glioblastoma: NRG Oncology RTOG Trial 0420. Int J Radiat Oncol Biol Phys :
Michalski, Jeff M; Moughan, Jennifer; Purdy, James et al. (2018) Effect of Standard vs Dose-Escalated Radiation Therapy for Patients With Intermediate-Risk Prostate Cancer: The NRG Oncology RTOG 0126 Randomized Clinical Trial. JAMA Oncol 4:e180039
Seider, Michael J; Pugh, Stephanie L; Langer, Corey et al. (2018) Randomized phase III trial to evaluate radiopharmaceuticals and zoledronic acid in the palliation of osteoblastic metastases from lung, breast, and prostate cancer: report of the NRG Oncology RTOG 0517 trial. Ann Nucl Med 32:553-560
Basch, Ethan; Dueck, Amylou C; Rogak, Lauren J et al. (2018) Feasibility of Implementing the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events in a Multicenter Trial: NCCTG N1048. J Clin Oncol :JCO2018788620
Regine, William F; Winter, Kathryn; Abrams, Ross A et al. (2018) Postresection CA19-9 and margin status as predictors of recurrence after adjuvant treatment for pancreatic carcinoma: Analysis of NRG oncology RTOG trial 9704. Adv Radiat Oncol 3:154-162

Showing the most recent 10 out of 591 publications